Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials
| Autor: | Pauligk C, Scholz M, Chen R, Salah-Eddin Al-Batran, Güntner M, Beiss B, Nadia Harbeck, Elke Jäger, W. Lerbs, Stopatschinskaja S |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Adolescent Anthracycline Mitomycin rechallenge Population Breast Neoplasms anthracycline Vinblastine Vinorelbine Disease-Free Survival Polyethylene Glycols Young Adult pegylated liposomal doxorubicin Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Anthracyclines Doxorubicin Prospective Studies Neoplasm Metastasis education Aged Clinical Trials as Topic education.field_of_study Antibiotics Antineoplastic Performance status Cumulative dose business.industry Middle Aged medicine.disease Metastatic breast cancer Surgery Treatment Outcome Drug Resistance Neoplasm Clinical Study Disease Progression Female metastatic breast cancer business medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Background: The aim of this study was to determine the activity of anthracycline rechallenge using pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC) previously treated with conventional anthracyclines. Methods: Pooled individual data from four prospective trials were used, and the primary end point of the pooled analysis was clinical benefit rate (CBR). The studies comprised 935 patients, of whom 274 had received PLD in the metastatic setting after prior exposure to conventional anthracyclines (rechallenge population). Results: The majority of patients were heavily pretreated. Previous anthracycline therapy was administered in the adjuvant (14%) or metastatic setting (46%), or both (40%). The overall CBR from rechallenge with PLD was 37.2% (95% CI, 32.4–42.0). In univariate analyses, the CBR was significantly higher in patients with less exposure to prior chemotherapy, in taxane-naive patients, and in patients with a favourable Eastern Cooperative Group performance status of 0 vs 1 vs 2 (53.3 vs 35.5 vs 18.2% P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|